Top Page
Micro-X Ltd.
(Sydney:MX1)
Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)
Micro-X Ltd. Business Overview & Revenue Model
Micro-X Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.05M | 13.05M | 15.22M | 15.01M | 8.97M | 3.77M |
| Gross Profit | 5.98M | 10.32M | 5.74M | -7.11M | -12.33M | -12.96M |
| EBITDA | -15.70M | -11.76M | -14.35M | -15.54M | -19.02M | -13.61M |
| Net Income | -13.89M | -13.89M | -9.77M | -10.75M | -17.09M | -14.73M |
Balance Sheet | ||||||
| Total Assets | 22.11M | 22.11M | 26.89M | 30.30M | 31.28M | 44.68M |
| Cash, Cash Equivalents and Short-Term Investments | 3.24M | 3.24M | 3.23M | 5.22M | 10.30M | 30.14M |
| Total Debt | 6.53M | 6.53M | 3.99M | 4.70M | 5.31M | 5.84M |
| Total Liabilities | 14.56M | 14.56M | 12.63M | 13.17M | 12.05M | 10.53M |
| Stockholders Equity | 7.55M | 7.55M | 14.26M | 17.13M | 19.22M | 34.15M |
Cash Flow | ||||||
| Free Cash Flow | -8.69M | -8.69M | -6.80M | -11.77M | -19.22M | -10.76M |
| Operating Cash Flow | -8.59M | -8.59M | -6.43M | -10.99M | -18.11M | -9.86M |
| Investing Cash Flow | -100.00K | -100.00K | -369.00K | -779.00K | -1.11M | -901.00K |
| Financing Cash Flow | 8.71M | 8.71M | 4.81M | 6.69M | -612.00K | 22.57M |
Micro-X Ltd. Technical Analysis
Micro-X Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$55.65M | ― | -2.50% | ― | 25.72% | 84.69% | |
45 Neutral | AU$63.44M | ― | -128.19% | ― | -14.25% | -22.83% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
44 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Micro-X Ltd. Corporate Events
Micro-X Ltd has reported significant achievements for the quarter ending September 2025, including securing its largest order to date with a $3.3 million purchase from the Malaysian Ministry of Health for Rover Plus units. This order marks a strategic expansion into Southeast Asia and highlights the company’s growing momentum in the healthcare market. Additionally, Micro-X is advancing its Head CT technology for stroke diagnosis, with upcoming trials in Australian hospitals and a world-first deployment in ambulances, supported by a $4.4 million government grant. These developments underscore Micro-X’s commitment to expanding its market presence and enhancing its product offerings.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd announced a delay in submitting an Appendix 3Y to the ASX due to an administrative oversight related to the issuance of shares to Non-Executive Director Ilona Meyer. The company reassures stakeholders that it has adequate arrangements to ensure future compliance with ASX Listing Rules. This announcement highlights Micro-X’s commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and supporting its strategic initiatives in expanding its market presence.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has announced its 2025 Annual General Meeting, which will be held virtually on November 11, 2025. Shareholders are encouraged to participate via Zoom, with voting facilitated through an online platform. The meeting will cover various resolutions, and shareholders are advised to submit proxy votes in advance to ensure their participation in case of technical issues. This virtual meeting format underscores the company’s commitment to accessibility and engagement with its stakeholders.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd., a leader in cold cathode X-ray technology, announced it received a $5.08 million R&D Tax Incentive from the Australian Tax Office for the financial year ending June 2025. This rebate, which supports the company’s R&D activities, was used to repay a previously accessed funding facility. Micro-X is also seeking an additional $0.31 million through an amendment, potentially increasing the total R&D rebate to $5.39 million. This financial boost aligns with the company’s guidance and supports its ongoing innovation in health and security markets, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has announced a significant $3.3 million order from the Malaysian Ministry of Health for its Rover Plus Mobile DR X-ray units, marking its first major order in Southeast Asia. This order, facilitated by the newly appointed Malaysian distributor Integrated Medical System Sdn Bhd, is a key milestone in Micro-X’s expansion strategy in the region. The delivery of these units is set to begin in October 2025, reinforcing the company’s position in the global market for mobile X-ray solutions. This development not only highlights the growing international recognition of Micro-X’s technology but also underscores the company’s strategy of partnering with experienced local distributors to accelerate market adoption.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has reached a significant milestone with its Head CT scanner, completing the first imaging test system ready for installation in Australian hospitals. This development marks a crucial step in a pivotal study comparing Head CT images with conventional CT scans for stroke diagnosis, potentially transforming stroke care by enabling rapid point-of-care diagnosis in ambulances. The company has developed advanced technologies, including miniature NEX Technology tubes and novel image reconstruction software, and is collaborating with the Australian Stroke Alliance and other partners. The successful deployment of this technology could revolutionize stroke treatment by allowing prehospital deployment in ambulances, thus moving the hospital to the patient and reducing disability.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has secured a $2.5 million contract extension from the U.S. Department of Homeland Security to enhance its Passenger Self-Screening Checkpoint detection algorithms. This extension increases the total value of contracts with DHS to $31.7 million, supporting the advancement of Micro-X’s detection software for airport security. The funding will accelerate software and machine learning developments, aiming to improve threat detection and enhance passenger experience while maintaining security. This development positions Micro-X as a key player in the airport security technology sector, with ongoing testing and deployment of its Checkpoint and baggage scanners in TSA facilities.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd has been awarded a $4.4 million grant by the Australian Government’s Industry Growth Program to develop and trial a stroke-capable ambulance equipped with their Head CT device. This initiative aims to revolutionize emergency stroke care by enabling faster diagnosis and treatment through in-ambulance imaging, potentially setting a new global standard. The project involves collaboration with the South Australian Ambulance Service and Royal Adelaide Hospital, and it will include developing new protocols and training for paramedics. The trial will serve as a global case study and support regulatory submissions for the Head CT device, with implications for improved health equity and stroke recovery rates worldwide.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has announced the quotation of 618,745 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.
Micro-X Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is accessible on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. This announcement underscores Micro-X’s dedication to maintaining robust governance practices, which can positively impact its reputation and stakeholder trust.
The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.